# Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

> **NCT07062354** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **SWOG Cancer Research Network** · enrollment: 50 (estimated)

## Conditions studied

- Head &Amp; Neck Cancer
- Head &Amp; Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

## Key facts

- **NCT ID:** NCT07062354
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-25
- **Primary completion:** 2028-10
- **Final completion:** 2029-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07062354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07062354, "Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07062354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*